LUDWIGSHAFEN, Germany, October 9 /PRNewswire/ --
Abbott (NYSE: ABT) today announced the opening of new development laboratories and a pilot plant facility that will research groundbreaking technologies and test large-scale production of newly developed drug formulations. The expansion is part of Abbott's global drug delivery business, SOLIQS, which is based in Ludwigshafen.
"Abbott is committed to advancing scientific innovation and bringing new medicines to patients," said John M. Leonard, M.D., senior vice president, Pharmaceuticals, Research and Development, Abbott. "Innovative drug formulation is critical to the development of effective new treatments that make a difference for patients."